C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. is trading at $4.20, down 1.52% on the session. The 50 day average sits at $3.90 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 63.8, which reads as strong, and MACD is bullish crossover. Volume is above average.

The nearest support is around $3.73 with resistance near $4.25, so that band frames the current range. Average daily movement is roughly $0.26, or about 6.3% of the share price, which is what any stop placement has to allow for. The overall health score of 62 out of 100 combines a trend score of 56, momentum of 88 and a risk score of 36.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.